ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
28 May 2020 - 11:00PM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today
announced that Mark Schneyer has been appointed to the newly
created position of Senior Vice President, Business Development and
Chief Business Officer. Mr. Schneyer will be responsible for
sourcing and executing business development opportunities and serve
as a member of the company’s Executive Management Committee. He
will report to Steve Davis, Chief Executive Officer.
“I am very excited to welcome Mark to ACADIA as his extensive
experience in the biopharmaceutical industry will be a valuable
addition as we continue to expand our pipeline through business
development,” said Mr. Davis. “We remain focused on leveraging our
research and development and commercial expertise as we advance our
business development strategies to position ACADIA for long-term
growth.”
Mr. Schneyer joins ACADIA from Pfizer Inc. where he most
recently was Vice President, Business Development, for the Upjohn
division. Mr. Schneyer joined Pfizer’s Worldwide Business
Development organization in 2011 and served in various business
development positions of increasing responsibility overseeing
strategic transactions spanning licensing agreements, product
acquisitions and divestitures, strategic collaborations and company
acquisitions. Prior to Pfizer, he was an investment banker at
Lazard and advised boards of directors and senior management teams
in the healthcare sector. Mr. Schneyer earned a Bachelor of Science
in economics with a concentration in finance from the Wharton
School of the University of Pennsylvania.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has
developed and commercialized the first and only medicine approved
for the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. ACADIA also has ongoing clinical
development efforts in additional areas with significant unmet
need, including dementia-related psychosis, major depressive
disorder, the negative symptoms of schizophrenia, and Rett
syndrome. This press release and further information about ACADIA
can be found at: www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization, and the fact that
past results of clinical trials may not be indicative of future
trial results. For a discussion of these and other factors, please
refer to ACADIA’s annual report on Form 10-K for the year ended
December 31, 2019 as well as ACADIA’s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200528005229/en/
Media Contact: ACADIA Pharmaceuticals Inc. Stephanie Fagan (858)
212-0534 media@acadia-pharm.com
Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2024 to May 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From May 2023 to May 2024